NIH Launches Phase 2 Trial to Track Venetoclax-Resistant CLL Clones in Patients
Clinical Design and Key Endpoints
NCT03986034, led by the National Heart, Lung, and Blood Institute (NHLBI), is a single-arm, open-label Phase 2 study designed to track early clonal evolution of chronic lymphocytic leukemia (CLL) cells during the venetoclax ramp-up phase. As of the verified ClinicalTrials.gov record in February 2026, the trial is actively recruiting, with a target enrollment of 75 patients and an estimated completion date of July 3, 2026. The primary endpoint is the proportion of patients experiencing clonal shift during the 5-week ramp-up period. This study focuses on understanding the biological processes underlying resistance over time, rather than a conventional efficacy trial focused on tumor reduction.
Drug and Patient Treatment Structure
Venclexta (venetoclax), a selective inhibitor of the BCL-2 protein that suppresses apoptosis, is an oral targeted therapy commercialized by AbbVie and Genentech, a Roche company. The NIH is managing a 5-week dose escalation starting at 20mg, after which patients are transferred to local hematologist-oncologists for monotherapy or combination therapy. Researchers will analyze the correlation between clonal changes and responses in blood, bone marrow, and lymph nodes, as well as circulating tumor DNA (ctDNA), minimal residual disease (MRD), progression-free survival (PFS), and overall survival (OS). In particular, the study compares early clonal shifts in patients receiving sequential BTK inhibitor therapy and those receiving venetoclax monotherapy to establish the basis for sequential treatment strategies.
Approval History and Competitive Landscape
The FDA granted accelerated approval for Venclexta in April 2016 for relapsed or refractory CLL with 17p deletion, and expanded the indication to relapsed CLL/small lymphocytic lymphoma (SLL) in June 2018 and to all adult CLL/SLL in May 2019. The initial review did not require external consultation, so it was not referred to the Oncologic Drugs Advisory Committee (AdComm). The current competitive standard includes BTK inhibitors such as Imbruvica (ibrutinib), Calquence (acalabrutinib), and Brukinsa (zanubrutinib), as well as anti-CD20 antibodies such as obinutuzumab and rituximab. Following BTK and BCL-2 therapy, pirtobrutinib, a non-covalent BTK inhibitor that received regular approval on December 3, 2025, is also a direct competitive option for relapsed patients.
Commercial and Strategic Significance
AbbVie's global net sales of Venclexta in 2025 were USD 2.792 billion, an 8% increase year-over-year, demonstrating that managing resistance and optimizing treatment duration are already impacting its substantial revenue base. In February 2026, the FDA approved the combination of Calquence and Venclexta for CLL/SLL patients without prior treatment, strengthening the competitiveness of fixed-duration, chemotherapy-independent combinations. If this study validates the link between early expansion of specific clones and MRD/PFS, it will enable the design of patient-specific sequential BTK inhibitor therapy, combination switching, or early rescue therapy. Conversely, if the results do not demonstrate a correlation between clonal changes and clinical progression, the scope of commercial application for biomarker-based treatment selection will be limited.
In the short term, NCT03986034, with its ongoing Phase 2 trial of 75 patients, will quantify clonal shifts during the 5-week ramp-up period, adding a new decision-making metric for predicting resistance to venetoclax, which was initially focused on managing tumor lysis syndrome. Given AbbVie's 2025 Venclexta sales of USD 2.792 billion, a correlation between MRD, ctDNA, clonal changes, and PFS will directly contribute to product lifecycle management by enabling expanded combination therapies and optimized treatment sequences. The competitive landscape is dominated by BTK inhibitors such as Brukinsa, Calquence, and Imbruvica, as well as pirtobrutinib, which has been approved for relapsed CLL, making strategies to retain patients after venetoclax resistance crucial for market share defense. In the medium to long term, the study will provide researchers with insights into the targets and patient selection biomarkers that evolve under BCL-2 selection pressure, and will provide the industry with a basis for designing clinical trials for next-generation BCL-2 inhibitors and BTK/anti-CD20 combination pipelines.
Source: ClinicalTrials.gov (api_ct)